Made of Genes Is Looking to Expand to the US and the Middle East and Grow by 50% in 2024

Made of Genes is looking to expand its borders. The Catalan start-up specialising in personalised precision healthcare is looking to expand abroad into regions where it does not yet have a strong presence, such as the Middle East or the United States. According to information provided by Laura Isús, general manager of Made of Genes, the company plans to launch in both territories with strategic partners soon.

The start-up currently operates in Spain, Portugal and Andorra, as well as having a presence with its own brand in other European countries and Latin America. In parallel to its international expansion, Made of Genes has planned new alliances with the Spanish public health system.

“We want to strengthen our ties with hospitals such as Sant Pau or Sant Joan de Déu in Barcelona in terms of preventive health,” says the director. Currently, Made of Genes works with almost all insurance companies and laboratories in the country. Among its clients and distributors are diagnostic laboratories such as Synlab, Eurofins-Megalab or Echevarne, as well as with different health service providers such as Cigna, Mercer-Marsh, AXA, DKV, Mapfre or MediFiatc.

Made of Genes’ plans for the remainder of the year include the addition of a new partner to its shareholding. At the beginning of this year, the company added FC Barcelona’s business school, Barça Innovation Hub (Bihub), to its ownership with the aim of providing solutions to meet the special needs of elite athletes.

Made of Genes plans to welcome a new partner into its capital soon

“We realised that health and sport cannot be separated, which is why we created this alliance with Bihub,” Isús emphasises. The intention between the two companies was to co-develop new biomedical intelligence solutions for optimising sports performance, preventing injuries and managing the health of elite athletes from a gender perspective.

As with the Catalan club, Made of Genes does not rule out creating new alliances before the end of the year. However, the Catalan start-up anticipates growing by 50% this year, “at the same rate at which we have been growing in recent years,” according to Isús.

Made of Genes specializes in implementing precision health in the real world. The company collects patient data using artificial intelligence (AI) algorithms to be able to provide more personalized recommendations in terms of health and quality of life. “One of our focuses is to continue advancing in non-communicable diseases , those that come from bad habits such as cancer or diabetes,” said the executive.

With offices in Esplugues de Llobregat (Barcelona), Made of Genes employs more than 35 workers with highly specialized profiles ranging from bioinformaticians to engineers, and next year it will reach its first decade of existence. The company was founded in 2015 as a business line of Genomcore. “Although we were visionaries in the use of AI, in recent years our business has been advancing along with the maturity that the health sector has had with this technology,” confirms Isús.

__

(Featured image by Nappy via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us